EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, RemeGen Co's Enterprise Value is HK$27,054.5 Mil.
RemeGen Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-559.9 Mil. Therefore, RemeGen Co's EV-to-FCF for today is -48.32.
The historical rank and industry rank for RemeGen Co's EV-to-FCF or its related term are showing as below:
HKSE:09995'
s EV-to-FCF Range Over the Past 10 Years
Min: -285.38 Med: -48.95 Max: -2.88
Current: -50.07
During the past 6 years, the highest EV-to-FCF of RemeGen Co was -2.88. The lowest was -285.38. And the median was -48.95.
HKSE:09995's EV-to-FCF is ranked worse than 100% of 389
companies
in the Biotechnology industry
Industry Median: 6.49
vs HKSE:09995: -50.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-14), RemeGen Co's stock price is HK$31.25.
RemeGen Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.782. Therefore, RemeGen Co's PE Ratio for today is At Loss.
RemeGen Co EV-to-FCF Historical Data
The historical data trend for RemeGen Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RemeGen Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where RemeGen Co's EV-to-FCF falls into.
RemeGen Co EV-to-FCF Calculation
RemeGen Co's EV-to-FCF for today is calculated as:
RemeGen Co's current Enterprise Value is HK$27,054.5 Mil.
RemeGen Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-559.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (HKSE:09995) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
RemeGen Co's share price for today is HK$31.25.
RemeGen Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2.782.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RemeGen Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of RemeGen Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09995 has been successfully added to your 